Santoro A M, Persico M, D'Urso A, Cunsolo A, Tkachuk O, Milardi D, Purrello R, Tundo G R, Sbardella D, Osmulski P A, Gaczynska M, Coletta M, Fattorusso C
National Research Council, Institute of Crystallography, Sede Secondaria di Catania, Catania, Italy.
Department of Pharmacy, University of Naples "Federico II", Napoli, Italy.
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2482892. doi: 10.1080/14756366.2025.2482892. Epub 2025 Apr 7.
Decreased proteasome activity is a hallmark of brain and retinal neurodegenerative diseases (Alzheimer's, Parkinson's diseases, glaucoma) boosting the search for molecules acting as proteasome activators. Based on the hypothesis of an electrostatic key code driving catalytic core particle (20S) activation by regulatory particles (RPs), we identified the tetra-anionic meso-Tetrakis(4-sulphonatophenyl)-porphyrin (H2TPPS) as a new activator of human proteasome. By means of an integrated approach, including bioinformatics, enzymatic kinetic analysis, atomic force microscopy, and dynamic docking simulations, we show how binding of H2TPPS affects the closed/open conformational equilibrium of human 20S to ultimately promote substrate gate opening and proteolytic activity. These outcomes support our hypothesis and pave the way to the rational discovery of new proteasome allosteric modulators able to reproduce the key structural elements of regulatory particles responsible for catalytic activation.
蛋白酶体活性降低是脑和视网膜神经退行性疾病(阿尔茨海默病、帕金森病、青光眼)的一个标志,这推动了对作为蛋白酶体激活剂的分子的研究。基于静电密钥编码驱动调节颗粒(RP)激活催化核心颗粒(20S)的假说,我们确定四阴离子中-四(4-磺酸苯基)-卟啉(H2TPPS)为人类蛋白酶体的一种新型激活剂。通过包括生物信息学、酶动力学分析、原子力显微镜和动态对接模拟在内的综合方法,我们展示了H2TPPS的结合如何影响人类20S的闭合/开放构象平衡,最终促进底物门打开和蛋白水解活性。这些结果支持了我们的假说,并为合理发现能够重现负责催化激活的调节颗粒关键结构元件的新型蛋白酶体变构调节剂铺平了道路。